Yu M, Poeschla E, Yamada O, Degrandis P, Leavitt M C, Heusch M, Yees J K, Wong-Staal F, Hampel A
Department of Biology, University of California at San Diego, La Jolla 92093-0665.
Virology. 1995 Jan 10;206(1):381-6. doi: 10.1016/s0042-6822(95)80053-0.
We have constructed a hairpin ribozyme targeted to cleave a conserved sequence in the HIV-1 pol gene. The ribozyme was modified to include a structure-stabilizing tetraloop. In vitro studies revealed a cleavage efficiency unprecedented for hairpin ribozymes (Kcat/Km = 75 min-1 microM-1). Stable retroviral vector transduction of this ribozyme gene in T-cell lines resulted in long-term ribozyme expression. As compared to control vector transduced T-cells, the pol ribozyme-transduced cells exhibited significant inhibition of different strains of HIV-1 virus production; this protection was greater when ribozyme expression was driven from an internal pol III promoter (adenovirus VA1) than when driven by a pol II promoter (the MMLV LTR). These results further demonstrate the potential of hairpin ribozymes as anti-HIV gene therapy agents and suggest possibilities for employing combinations of independently targeted hairpin ribozymes.
我们构建了一种靶向切割HIV-1 pol基因保守序列的发夹状核酶。该核酶经过修饰,包含一个稳定结构的四环。体外研究显示,其切割效率是发夹状核酶前所未有的(催化常数/米氏常数 = 75分钟-1微摩尔-1)。该核酶基因在T细胞系中的稳定逆转录病毒载体转导导致了核酶的长期表达。与对照载体转导的T细胞相比,pol核酶转导的细胞对不同毒株的HIV-1病毒产生具有显著抑制作用;当核酶表达由内部pol III启动子(腺病毒VA1)驱动时,这种保护作用比由pol II启动子(莫洛尼鼠白血病病毒长末端重复序列)驱动时更强。这些结果进一步证明了发夹状核酶作为抗HIV基因治疗药物的潜力,并提示了使用独立靶向的发夹状核酶组合的可能性。